Summary. Using a prospective randomised double-blind crossover design, the effect of the angiotensin converting enzyme inhibitor enalapril compared to a placebo was studied in 18 normotensive, normoalbuminuric Type 1 (insulin-dependent) diabetic children. Each patient had a high normal or dearly elevated glomerular filtration rate (145 ml.min -1. 1.73 m 2 or higher) in the 6 months prior to the study. Enalapril, 0.5 mg.kg -1. day -1, was given for 4 weeks followed by placebo for 4 weeks, or vice versa. At the end of each period, glomerular filtration rate, renal plasma flow, blood pressure, plasma renin activity, and converting enzyme activity were determined. Enalapril caused significant reduction (p= < 0.001) in blood pressure and converting enzyme activity and a rise in plasma renin activity. A slight but not significant rise in glomerular filtration rate and renal plasma flow without change in filtration fraction was observed. These data suggest that the renin angiotensin system is not involved in the glomerular hyperfiltration of Type 1 diabetes, and can be interpreted as showing no evidence for the presence of intraglomerular hypertension in these patients.
Elevation of glomerular filtration rate (GFR) and renal plasma flow (RPF) is present in a high proportion of patients with Type 1 (insulin-dependent) diabetes mellitus [1] . Although these functional changes are present early in the course, even at time of diagnosis and persist for years, their significance is unclear, and it is not established whether they relate to the later development of diabetic nephropathy. One retrospective study in 12 patients has correlated the presence of glomerular hyperfiltration early in diabetes with raised urinary albumin excretion and reduced GFR a decade later [2] . Glomerular haemodynamic alterations have been well documented in a variety of experimental models of renal disease in the rat, including experimentally induced diabetes mellitus [3] . These changes include increased GFR, RPF and intraglomerular capillary pressure, as well as reduced glomerular afferent and efferent arteriolar resistance. The sclerosing glomerular lesions, progressive reduction in GFR, and albuminuria which develop are thought to be a consequence of these * Recipient of the Schering Award of the Canadian Society of Clinical Investigation during the period of this research haemodynamic aberrations, regardless of the particular experimental model, This has led to a unifying hypothesis to explain the development and progression of glomerular injury in a variety of experimental glomerular diseases. It is suggested that elevation of intraglomerular capillary pressure, or "glomerular hypertension", is the principal haemodynamic perturbation responsible for glomerular damage [3] [4] [5] [6] [7] [8] . The hypothesis has also been invoked to explain the progression of various glomerular disorders in man and the development of human diabetic nephropathy [9] [10] [11] [12] [13] .
In experimental animals, angiotensin converting enzyme (ACE) inhibitors and reduction in dietary protein intake have each been shown to alter glomerular haemodynamic parameters, causing normalisation of raised glomerular capillary pressure although other haemodynamic perturbations may persist [3, 6] . This is accompanied by prevention of both glomerulosclerosis and albuminuria, or, in circumstances where abnormalities have already developed, in the arrest of progression [6] . The reduction in glomerular hypertension is the result of decreased efferent arteriolar resistance due to diminished angiotensin II production consequent to ACE inhibition [14] . In the present study, we investigated using a double blind cross over design the effect on renal function of 4weeks treatment with the ACE-inhibitor, enalapril (kindly supplied by Merck Sharp and Dohme -Chibret, France) in normotensive, normoalbuminuric Type 1 diabetic children with a high normal or elevated GFR (145 ml-rain -1.1.73 m 2 or higher) determined in the 6 month period prior to the study. Patients were considered normotensive according to the norms and methods for determining blood pressure in children currently used in France [15] . We reasoned that if the GFR fell with ACE inhibition therapy, a likely explanation would be that raised glomerular pressure, a haemodynamic variable known to cause increased GFR, had been normalised by reduction in efferent arteriolar resistance and that raised glomerular pressure was contributory to the elevated GFR seen in Type I diabetes.
Subjects and methods

Subjects
All patients were recruited from the Endocrine Department of the Hfpital Necker-Enfants Malades, Paris, France. As part of a clinical protocol to evaluate renal function in diabetic patients, GFR, RPF, urinary albumin excretion rate and plasma renin activity have been determined in these patients annually since 1984. From the patients evaluated in the 6 month period prior to May 1, 1987 , all with GFR> 145 ml-min -1.1.73 m 2 were considered for inclusion in the study. Normal values for GFR in this laboratory are 123+18 (range 97-152; values corrected for plasma water content) and for RPF 695 + 110 (range 503-909) ml. min-1.1.73 m2). Twenty patients were selected based on an assessment by the diabetologist of the relative stability of the diabetic control, the reliability and likely compliance in following the treatment regimen, and willingness to undergo the necessary renal functional evaluations. All subjects or their parents gave informed consent, and the study was approved by the hospital ethics committee. No attempt was made to alter diet or glycaemic control during the study period nor was any objective measurement of dietary protein intake undertaken. Each patient was normotensive as determined by sequential blood pressure measurements during the preceding year. Blood pressure was considered normal if systolic and diastolic values fell within the 95th percentile for age. Relevant clinical data for each patient is given in Table 1 . Of the twenty selected for randomisation eighteen completed the study.
Study Design
Patients were randomised for sequence of therapy in a double blind crossover study to receive either 4'weeks of enalapril in a dose of 0.5 mg. kg-1. day-1 to a maximum of 20 mg, followed by 4 weeks of placebo, or vice versa, i. e. placebo for 4 weeks followed by 4 weeks of enalapril. Both placebo and enalapril were given in two divided doses daily. On the morning prior to the end of the treatment period, the patient was admitted to the clinical investigation unit for renal function studies (GFR and RPF) and for studies mentioned below. The studies were carried out between 8:30 and 14.00hours. Each patient was questioned about possible side effects and general state of health. The number of pills for each period was counted, and each patient was given more pills than required to complete the period. The unused amount was returned and the'. remaining number was counted. The pill count was used as one means of determining adherence to the therapeutic regimen. The last dose of each treatment regimen was taken at breakfast before the studies.
Studies of renal function and related tests
Before commencing the renal function studies (done in the recumbent position in bed) and while the patient was upright, blood was drawn for measurement of plasma renin activity, creatinine, electrolytes, hemoglobin Alc~ converting enzyme activity and glucose. Blood pressure was monitored both by standard mercury manometer and by using a Dynamap TM 845 XT (Critikon Inc., Tampa, Fla. USA) continuous recorder during the approximately 3 h long recumbent period of the renal function tests and again after a subsequent period of 30 min in the upright position. For the purposes of analysis, we report the mean arterial pressure values at 150 min recumbent and after 30 min upright. In six patients, because of minor symptoms -eg. nausea, lightheadedness, the study was discontinued before the upright blood pressure at 30 rain was determined.
Inulin and paraamino hippurate clearances were used to determine GFR and RPF respectively using a single injection technique with measurement of the plasma decay curve over a 3 h period [16] . Inulin was measured following treatment of the plasma samples with glucose oxidase to reduce interference by glucose using an anthrone autoanalyser method [17] and paraamino hippurate was measured by the method of Smith [18] . Although inulin clearance using a constant infusion technique with accurately timed urine specimens is the most reliable means of measuring glomerular filtration rate, a single injection technique using inulin and paraamino hippurate or other tracers with measurement of plasma decay curve of the tracer is well accepted for routine use in many centers (19) (20) (21) (22) . The method we use involves injection of inulin 50 mg/kg and paraamino hippurate 8 mg/kg. The decay curve is analysed as the sum of two exponentials, with blood samples taken at 0, 5, 10, 15, 30, 45, 60, 90, 120, 150 and 180 rain. Because of the large number of blood samples, the curves obtained fit well with the theory of exponential decay. The coefficients of variance of replicate measurements for inulin and paraamino hippurate are 2.8 and 2.5 per cent respectively.
Urinary albumin excretion was measured on a freshly voided specimen just prior to beginning the renal function studies and also on the timed urine specimens voided during the 3 h test. Albumin concentration was measured using a commercial kit (Pharmacia Diagnostics AB, Uppsala, Sweden) and expressed as the ratio of the concentration of albumin to creatinine (rag albumin.mmol -~ creatinine, normal < 4), and as jxg albumin excreted per min, (normal < 15).
Plasma renin activity was measured by a micromethod (23) and results were expressed as ng-ml-l.h-l; normal values are 4 (range 1.0-8.5) recumbent, and 6.3 (range 4.3-8.1) upright. Converting enzyme activity was measured by the method of Lieberman (24) and results expressed as mmol-ml-~-min -~ (normal values are 21.5 + 5.4). Haemoglobin Ale was measured by high performance liquid chromatography; normal values are less than 4.7%.
Statistical analysis
All values are expressed as mean + SD. Differences were analysed using a paired Student t-test; p values < 0.05 were considered significant. No differences attributable to treatment sequence were seen; thus, all of the enalapril data are pooled together and compared to all of the placebo data regardless of treatment sequence. 20.
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Plasma renin achwty Table 1 presents the basic clinical and laboratory data. Eighteen patients, 9 male and 9 female, age 8-20 years completed the study. Mean duration of diabetes was 6.2 years; mean haemoglobin Alc level was the same, 7.8%, at the end of each treatment period. Except for two patients (7 and 16) whose diabetic control was rather poor, the other values for hemoglobin AI c were comparable to our usual current experience with a large number of diabetic children. No side effects attributable to the medication were seen.
The mean values for GFR after enalapril and placebo were 160 arid 152ml.min-l.l.73m 2 respectively (Fig.l) , and for RPF, 790 and 743 ml-min -t 9 1.73 m 2. Although the mean values for each of these parameters were higher after enalapril than after placebo, these differences are not significant. The filtration fraction was the same (20%) following each treatment period. The values for GFR are omitted for three periods because it was considered that the biochemical determinations in these specific instances were not accurate, and it was not possible to obtain a good fitting of the plasma falloff curve for inulin. One patient (no. 7) had an apparent allergic reaction to PAH during a prior study and so this test was not repeated during the present study. Since blood glucose levels may alter glomerular filtration rate, the mean values of determinations taken throughout the course of each patient's renal function study were compared following both enalapril and placebo treatment. The values following enalapril and placebo were 13.03 mmol.L+3.64 and 11.75+5.59 respectively. These differences are not significant. There was a significant difference (p= < 0.001) in plasma renin activity following enalapril and placebo treatment. Every patient showed an elevation following enalapril, ranging from a 5 to 65 fold increase. Figure 2 graphically shows this difference by comparing each individual's value following enalapril with the value following placebo. There was a significantly lower (p = < 0.00001) converting enzyme activity level following enalapril in comparison to the post placebo level, mean 6.9 vs 36.9 mmol-m1-1-min -1 respectively. This was seen in all patients except one (no. 5) whose post enalapril and post placebo values were essentially the same (29.6 and 28), even though the plasma renin activity was clearly elevated following enalapril as compared to the values after placebo (21 vs 3.1). There was close correspondence, within 4 pills, between the number of pills which should have been taken during each treatment regimen and the number of pills which were not returned, ie. presumably taken by the patient. Taken together, we interpret these three lines of evidenceplasma renin activity, converting enzyme activity, and pill counts as evidence in favor of excellent compliance. (Fig. 3) and upright mean arterial pressure levels were significantly lower (p= < 0.001 and < 0.05 respectively) following enalapril than placebo. Urinary albumin excretion levels were within normal limits in all but one patient (no.6). Regardless of whether the results are expressed as ~tg-min -1 or mg-mmol-t creatinine in the urine obtained during the period of the renal function studies, or as rag-mmo1-1 creatinine in the specimen obtained just prior to commencing these studies, no significant differences were seen after enalapril vs placebo treatment. It is of interest that a marked reduction in albumin excretion rate was seen following enalapril (62.6 to 3.9 ~tg. min-1) in patient 6, the only patient with elevated pre-treatment values.
Discussion
The cause of glomerular hyperfiltration in Type 1 diabetes is unknown and so is its importance in the pathogenesis of diabetic nephropathy. Both GFR and RPF rise in relation to blood glucose level in normal and diabetic subjects [25] [26] [27] [28] . Furthermore, there is good correlation between dietary protein intake, as estimated by urinary urea excretion, and GFR in both normal and diabetic subjects [29] . Other hormonal or metabolic disturbances which occur in diabetes have also been implicated. These include the presence of ketone bodies, which cause increase in RPF and GFR in both normal and diabetic subjects [30] , hyperglucagonemia [3q, and elevated levels of growth hormone [32] . The magnitude of elevation in GFR associated with these individual factors is smaller than that characteristically seen in diabetic subjects; however, it is possible that each contributes in its own way and that the effects are additive.
Moreover, glomerular structural alterations are seen even early in the course. These consist of increase in glomerular size and capillary filtration surface area. Since filtration surface area is one of the two determinants of the ultrafiltration coefficient -Kf, increase in surface area could directly affect GFR. Indeed, a close correlation exists between glomerular capillary surface area and GFR in both normal and diabetic subjects over a wide range of values from hyper-to hypofiltration [33, 34] . Thus, the etiology of glomerular hyperfiltration in Type 1 diabetes is probably multifactorial involving both the structural and physiological determinants of glomerular ultrafiltration. Our data provide no evidence that ACE inhibition altered GFR or RPF. Thus, the renal functional changes in Type 1 diabetes are probably independent of angiotensin II.
Attention has focused on the elevation of GFR as the central renal functional change of early diabetes. Nevertheless, RPF is also elevated. This is important because of the established direct effect of RPF on GFR in the experimental animal, a situation which presumably pertains to the human being. Thus, elevation of GFR in Type 1 diabetes may be principally a consequence of elevated RPF. A generalised capillary hyperfusion involving many organs and tissues is recognised in diabetes, although a unifying hypothesis has not been developed to explain this phenomenon.
Apart from the raised RPF and increased glomerular capillary filtration surface area mentioned above, renal micropuncture studies in some models of experimental diabetes in the rat have shown an elevated intracapillary glomerular pressure [3, 35] . A proposed mechanism involves increased secretion of atrial natriuretic factor which causes a reduction in afferent but not efferent glomerular arteriolar resistance, thus leading to raised glomerular intracapillary pressure [35] . This glomerular pressure increase enhances the net ultrafiltration pressure and could explain, at least in part, the elevated GFR seen in some models of experimental diabetes.
We view with caution extrapolation of data derived from micropuncture studies in diabetic rats to the diabetic patient, since a number of these models [36] [37] [38] [39] [40] do not demonstrate the haemodynamic changes, in particular, glomerular hypertension, which is felt to be critical for the development of nephropathy. Moreover, the focal glomeruloscIerotic lesions attributed to glomerular hypertension are unlike the classical lesions of human or experimental diabetes. Nevertheless, it is of interest to examine our data in the context of the experimental observations while recognising the difficulty in interpreting glomerular functional changes without precise measurements of the glomerular pressure and flow parameters which govern ultrafiltration.
In theory, ACE inhibition should reduce efferent arteriolar tone, thus reducing glomerular capillary pressure to normal levels if it is elevated. Therefore, if raised GFR in Type 1 diabetes was primarily related to intraglomerular hypertension, a reduction in GFR would reasonably be expected to occur following enalapril therapy. This was not seen; indeed mean levels of both GFR and RPF rose, although not significantly. Since increased glomerular plasma flow can increase GFR in the absence of raised glomerular pressure, and since RPF and filtration fraction remained unchanged after enalapril, it is reasonable to ascribe glomerular hyperfiltration in diabetic subjects to elevated RPF, with or without increased filtering surface. It is unnecessary to invoke the additional factor of raised intracapillary pressure. Since this is the hemodynamic perturbation which is considered to be harmful, it may be appropriate to reconsider the proposed importance of glomerular haemodynamic alterations in the pathogenesis of diabetic nephropathy in human subjects.
